Altamira Therapeutics Ltd

CYTO12 Dec 2024
Healthcare
$0.45
0.00 (-0.40%)
Lowest Today
$0.45
Highest Today
$0.46
Today’s Open
$0.45
Prev. Close
$0.46
52 Week High
$5.79
52 Week Low
$0.4
To Invest in Altamira Therapeutics Ltd

Altamira Therapeutics Ltd

Healthcare
CYTO12 Dec 2024
0.00 (-0.40%)
1M
3M
6M
1Y
5Y
Low
$0.45
Day’s Range
High
$0.46
0.45
52 Week Low
$0.4
52-Week Range
52 Week High
$5.79
0.4
1 Day
-
1 Week
-2.5%
1 month return
+11.9%
3 month return
-45.35%
6 month return
-64.92%
1 Year return
-86.94%
3 Years return
-99.91%
5 Years return
-99.91%
10 Years return
-
Institutional Holdings
Armistice Capital, LLC
2.68
Citadel Advisors Llc
0.39
Fidelity Nasdaq Composite Index
0.06
Group One Trading, LP
0
LRI Investments, LLC
0
Morgan Stanley - Brokerage Accounts
0
Tower Research Capital LLC
0
Fundamentals
Market Cap
1.85 mln
PB Ratio
0.31
PE Ratio
0.27
Enterprise Value
2.32 mln
Total Assets
7.69 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Organisation
Altamira Therapeutics Ltd
Employees
10
Industry
Biotechnology
CEO
Dr. Thomas  Meyer Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step